Björkelid Christofer, Bergfors Terese, Henriksson Lena M, Stern Ana Laura, Unge Torsten, Mowbray Sherry L, Jones T Alwyn
Department of Cell and Molecular Biology, Uppsala University, Biomedical Center, Box 596, SE-75124 Uppsala, Sweden.
Acta Crystallogr D Biol Crystallogr. 2011 May;67(Pt 5):403-14. doi: 10.1107/S0907444911006160. Epub 2011 Apr 8.
A number of pathogens, including the causative agents of tuberculosis and malaria, synthesize isopentenyl diphosphate via the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway rather than the classical mevalonate pathway found in humans. As part of a structure-based drug-discovery program against tuberculosis, IspD, the enzyme that carries out the third step in the MEP pathway, was targeted. Constructs of both the Mycobacterium smegmatis and the Mycobacterium tuberculosis enzymes that were suitable for structural and inhibitor-screening studies were engineered. Two crystal structures of the M. smegmatis enzyme were produced, one in complex with CTP and the other in complex with CMP. In addition, the M. tuberculosis enzyme was crystallized in complex with CTP. Here, the structure determination and crystallographic refinement of these crystal forms and the enzymatic characterization of the M. tuberculosis enzyme construct are reported. A comparison with known IspD structures allowed the definition of the structurally conserved core of the enzyme. It indicates potential flexibility in the enzyme and in particular in areas close to the active site. These well behaved constructs provide tools for future target-based screening of potential inhibitors. The conserved nature of the extended active site suggests that any new inhibitor will potentially exhibit broad-spectrum activity.
许多病原体,包括结核病和疟疾的病原体,通过2-C-甲基-D-赤藓糖醇4-磷酸(MEP)途径合成异戊烯基二磷酸,而不是通过人类中发现的经典甲羟戊酸途径。作为针对结核病的基于结构的药物发现计划的一部分,MEP途径第三步的执行酶IspD成为了目标。构建了适合进行结构和抑制剂筛选研究的耻垢分枝杆菌和结核分枝杆菌的酶构建体。获得了耻垢分枝杆菌酶的两种晶体结构,一种与CTP形成复合物,另一种与CMP形成复合物。此外,结核分枝杆菌酶与CTP形成复合物后进行了结晶。在此,报告了这些晶体形式的结构测定和晶体学精修以及结核分枝杆菌酶构建体的酶学特性。与已知的IspD结构进行比较,确定了该酶结构保守的核心。这表明该酶存在潜在的灵活性,特别是在靠近活性位点的区域。这些性能良好的构建体为未来基于靶点筛选潜在抑制剂提供了工具。扩展活性位点的保守性质表明,任何新的抑制剂都可能具有广谱活性。